Tags

Type your tag names separated by a space and hit enter

Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study.
J Natl Cancer Inst 2015; 107(2)JNCI

Abstract

BACKGROUND

Cutaneous melanoma is the fifth most common cancer in the United States. Modifiable risk factors, with the exception of exposure to ultraviolet radiation (UVR), are poorly understood. Coffee contains numerous bioactive compounds and may be associated inversely with melanoma. However, previous epidemiological evidence is limited.

METHODS

Coffee intake was assessed at baseline with a food frequency questionnaire in the National Institutes of Health-AARP prospective cohort study. Among 447 357 non-Hispanic whites who were cancer-free at baseline, 2904 incident cases of malignant melanoma were identified during 4 329 044 person-years of follow-up, with a median of 10.5 years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee intake and subsequent melanoma risk with non-coffee drinkers as the reference group. Statistical tests were two-sided, and P values less than .05 were interpreted as statistically significant.

RESULTS

The highest category of coffee intake was inversely associated with malignant melanoma (≥4 cups/day: HR = 0.80, 95% CI = 0.68 to 0.93, P trend = .01). This association was statistically significant for caffeinated (≥4 cups/day: HR = 0.75, 95% CI = 0.64 to 0.89, P trend = .01) but not for decaffeinated coffee (P trend = .55).

CONCLUSIONS

Higher coffee intake was associated with a modest decrease in risk of melanoma in this large US cohort study. Additional investigations of coffee intake and its constituents, particularly caffeine, with melanoma are warranted.

Authors+Show Affiliations

Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM). erikka.loftfield@nih.gov.Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25604135

Citation

Loftfield, Erikka, et al. "Coffee Drinking and Cutaneous Melanoma Risk in the NIH-AARP Diet and Health Study." Journal of the National Cancer Institute, vol. 107, no. 2, 2015.
Loftfield E, Freedman ND, Graubard BI, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst. 2015;107(2).
Loftfield, E., Freedman, N. D., Graubard, B. I., Hollenbeck, A. R., Shebl, F. M., Mayne, S. T., & Sinha, R. (2015). Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. Journal of the National Cancer Institute, 107(2), doi:10.1093/jnci/dju421.
Loftfield E, et al. Coffee Drinking and Cutaneous Melanoma Risk in the NIH-AARP Diet and Health Study. J Natl Cancer Inst. 2015;107(2) PubMed PMID: 25604135.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. AU - Loftfield,Erikka, AU - Freedman,Neal D, AU - Graubard,Barry I, AU - Hollenbeck,Albert R, AU - Shebl,Fatma M, AU - Mayne,Susan T, AU - Sinha,Rashmi, Y1 - 2015/01/20/ PY - 2015/1/22/entrez PY - 2015/1/22/pubmed PY - 2015/2/20/medline JF - Journal of the National Cancer Institute JO - J. Natl. Cancer Inst. VL - 107 IS - 2 N2 - BACKGROUND: Cutaneous melanoma is the fifth most common cancer in the United States. Modifiable risk factors, with the exception of exposure to ultraviolet radiation (UVR), are poorly understood. Coffee contains numerous bioactive compounds and may be associated inversely with melanoma. However, previous epidemiological evidence is limited. METHODS: Coffee intake was assessed at baseline with a food frequency questionnaire in the National Institutes of Health-AARP prospective cohort study. Among 447 357 non-Hispanic whites who were cancer-free at baseline, 2904 incident cases of malignant melanoma were identified during 4 329 044 person-years of follow-up, with a median of 10.5 years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee intake and subsequent melanoma risk with non-coffee drinkers as the reference group. Statistical tests were two-sided, and P values less than .05 were interpreted as statistically significant. RESULTS: The highest category of coffee intake was inversely associated with malignant melanoma (≥4 cups/day: HR = 0.80, 95% CI = 0.68 to 0.93, P trend = .01). This association was statistically significant for caffeinated (≥4 cups/day: HR = 0.75, 95% CI = 0.64 to 0.89, P trend = .01) but not for decaffeinated coffee (P trend = .55). CONCLUSIONS: Higher coffee intake was associated with a modest decrease in risk of melanoma in this large US cohort study. Additional investigations of coffee intake and its constituents, particularly caffeine, with melanoma are warranted. SN - 1460-2105 UR - https://www.unboundmedicine.com/medline/citation/25604135/Coffee_drinking_and_cutaneous_melanoma_risk_in_the_NIH_AARP_diet_and_health_study_ L2 - https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju421 DB - PRIME DP - Unbound Medicine ER -